Addiction

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.

In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.

A new study showed how taking alcohol use disorder medication following an alcohol-related hospitalization discharge was linked to a reduction in return to hospital in 30 days.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

Cancer patients with behavioral health disorders, such as substance abuse, eating disorders, and sleep disorders have a 7.76% increase in health care costs, a new study found.

A study found 27.5% of individuals who had an emergency department for cannabis use were diagnosed with a new anxiety disorder within 3 years. However, only 5.6% of the general population developed a new anxiety disorder.

A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.

Mindfulness-Oriented Recovery Enhancement plus methadone treatment is a promising treatment option for patients with opioid use disorder, having been significantly associated with less return to drug use and methadone treatment dropout, a new study found.

Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.

From 2018 to 2021, the deaths among U.S. pregnant and postpartum women aged 35 – 44 years old more than tripled, a new study found.

A newly developed prediction model for opioid treatment relapse includes 4 consecutive week urine drug screenings to test for risk of return.

The COVID-19 pandemic skyrocketed already high rates of alcohol consumption and related liver disease to unprecedented levels. Addiction specialists and hepatologists are still looking for the best path out.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

Trends show e-cigarette use in patients with CVD decreased from 2015 to 2019, but rebounded in 2019, potentially owing to the COVID-19 pandemic.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

"Depression causes a large public health burden, and alcohol-related behavior is a potentially modifiable risk factor," Dr. Gemma Hammerton writes.

RiVive is the second nonprescription naloxone product approved by the FDA, signaling a proactive effort to increase accessibility and consumer availability of life-saving medication.

Data corresponding with DSM-IV symptoms were gathered around ages 18, 21, and 23 years and the primary outcome was depression at age 24.

The American Heart Association has released a new scientific statement on the current science on the health effects of e-cigarette use and calls for more studies regarding their long-term impact.

A Lynchburg-based clinic was able to cure hepatitis C in all follow-through patients with substance abuse who underwent a comprehensive care plan over 8 weeks.

The analysis of 500+ patients with ADHD shows no statistically significant evidence linking stimulant treatment to later substance use, indicating that stimulant medication did not increase or decrease the risk of substance use in adolescence or adulthood.

The data provide promising results, yielding a smoking abstinence rate of 26.4% in the intervention group at 18 months.